These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 3143016

  • 1. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study.
    Heney NM, Koontz WW, Barton B, Soloway M, Trump DL, Hazra T, Weinstein RS.
    J Urol; 1988 Dec; 140(6):1390-3. PubMed ID: 3143016
    [Abstract] [Full Text] [Related]

  • 2. First-line chemotherapy of superficial bladder cancer: mitomycin vs thiotepa.
    Heney NM.
    Urology; 1985 Oct; 26(4 Suppl):27-9. PubMed ID: 3931325
    [Abstract] [Full Text] [Related]

  • 3. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
    Zincke H, Benson RC, Hilton JF, Taylor WF.
    J Urol; 1985 Dec; 134(6):1110-4. PubMed ID: 3932685
    [Abstract] [Full Text] [Related]

  • 4. A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers.
    Flanigan RC, Ellison MF, Butler KM, Gomella LG, McRoberts JW.
    J Urol; 1986 Jul; 136(1):35-7. PubMed ID: 3086575
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C.
    Soloway MS, Perry A.
    J Urol; 1987 May; 137(5):871-3. PubMed ID: 3106653
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Severe bladder contracture in patient receiving intravesical mitomycin C for superficial bladder cancer.
    Baker WC, Russo MA, deVere White RW.
    Urology; 1987 Oct; 30(4):357-8. PubMed ID: 3116739
    [Abstract] [Full Text] [Related]

  • 16. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
    Soloway MS, Jordan AM, Murphy WM.
    Prog Clin Biol Res; 1989 Oct; 310():215-36. PubMed ID: 2505268
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder.
    Pavlotsky A, Eidelman A, Barak F, Alon H, Horn Y.
    J Surg Oncol; 1989 May; 41(1):9-11. PubMed ID: 2497274
    [Abstract] [Full Text] [Related]

  • 18. Intravesical mitomycin C for the treatment of recurrent superficial bladder tumours.
    Hetherington JW, Newling DW, Robinson MR, Smith PH, Adib RS, Whelan P.
    Br J Urol; 1987 Mar; 59(3):239-41. PubMed ID: 3105631
    [Abstract] [Full Text] [Related]

  • 19. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer.
    Br J Urol; 1985 Dec; 57(6):680-5. PubMed ID: 2867800
    [Abstract] [Full Text] [Related]

  • 20. Intravesical chemotherapy for superficial carcinoma of the bladder.
    Foo KT, Tan EC, Tung KH, Tock EP.
    Singapore Med J; 1991 Dec; 32(6):420-2. PubMed ID: 1788600
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.